ACEI类药物与潜在的肺癌风险  

ACEI drugs and potential risk of lung cancer

作　　者：胡蕴然 车坷科 Hu Yunran;Che Keke(School of Basic Medicine and Clinic Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Department of Pharmacology,Chongqing General Hospital,University of Chinese Academy of Sciences,Chongqing 400014,China)

机构地区：[1]中国药科大学基础医学与临床药学学院,南京211198 [2]中国科学院大学重庆医院/重庆市人民医院药学部,重庆400014

出　　处：《保健医学研究与实践》2020年第4期85-89,共5页Health Medicine Research and Practice

摘　　要：近期,加拿大科学家发表文章警示常用的一线降压药血管紧张素转换酶抑制剂(ACEIs)的长期使用会增加罹患肺癌的风险,引起医学界和患者的广泛关注和担忧。本文对ACEIs类药物潜在的肺癌风险进行系统回顾,发现目前尚存在较多争议,需要后期对更多长期服用ACEIs的人群进行回顾性分析,并开展更深入的作用机制研究以为该类药物的安全使用及药学监护提供参考。Recently,Canadian scientists published an article warning that long-term use of angiotensin converting enzyme inhibitor(ACEIs),a commonly used first-line antihypertensive drug,will increase the risk of lung cancer.The relationship between long-term chronic drug use of ACEIs and tumorigenesis has been paid much attention,and the literature shows that there is a risk of lung cancer.In this paper,we systematically review the potential risk of lung cancer of ACEIs drugs,and find that there is still much controversy at present.It is still necessary to conduct a retrospective study on more people who take ACEIs for a long time,and to carry out more indepth basic research to further clarify the mechanism of ACEIs on the occurrence of lung cancer.To provide reference for the safe use and pharmaceutical care of this kind of drugs.

关 键 词：血管紧张素转换酶抑制剂 肿瘤 肺癌 药学监护 

分 类 号：R969.3[医药卫生—药理学]